Tetrahedron Letters 54 (2013) 1765-1767

Contents lists available at SciVerse ScienceDirect

**Tetrahedron Letters** 

journal homepage: www.elsevier.com/locate/tetlet

# Study of aza-cyclization of $\alpha$ , $\beta$ -unsaturated carbonyl moieties and synthetic application to hexahydroapoerysopine

Hee Dong Kim, Guncheol Kim\*

Department of Chemistry, College of Natural Sciences, Chungnam National University, Daejon 305-764, Republic of Korea

#### ARTICLE INFO

Article history: Received 7 January 2013 Revised 22 January 2013 Accepted 23 January 2013 Available online 31 January 2013

### Keywords: Aza-cyclization Polycyclic alkaloid Hexahydroapoerysopine Azepine

## ABSTRACT

Aza-cyclization of  $\alpha$ , $\beta$ -unsaturated carbonyl moieties with free amine has been studied. An azepine alkaloid, hexahydroapoerysopine, has been synthesized from an enone-ester in a concise manner through the aza-cyclization followed by reductions.

© 2013 Elsevier Ltd. All rights reserved.

Polycyclic hetero-compounds containing nitrogen are frequently encountered in natural alkaloid compounds, and the structurally related products containing synthetic drugs have shown numerous physiological activities.<sup>1</sup> Especially, the azepine compounds arranged with other rings around have been attracted by many synthetic chemists because of skeletal challenges as well as biological applications.<sup>2,3</sup> Most of the approaches toward the azepine compounds have been focused on the efficient formation of the central seven-membered ring (Fig. 1). As an extension of our interests on the synthesis of the azepine natural products,<sup>4</sup> we want to explore an aza-cyclization reaction by free amine. The free amine addition to the carbonyl or olefin of  $\alpha$ , $\beta$ -unsaturated carbonyl derivatives for the formation of azepine ring has been rarely applied in natural alkaloid synthesis.<sup>5</sup>

Preliminarily, we tested the selectivity of cyclization pathways on compound **3**, condensation to intermediate **5**, or addition to **4**. Compound **3** would be obtained by the deprotection of *N*-Boc protected precursor of **3**. The precursor could be readily prepared by the known Suzuki coupling reaction pathway.<sup>6,7</sup> Upon refluxing the precursor with CF<sub>3</sub>CO<sub>2</sub>H in toluene followed by addition of K<sub>2</sub>CO<sub>3</sub> and concentration, an unstable intermediate was obtained, and the crude product was reduced readily with NaCNBH<sub>3</sub> to enamine compound **6** in quantitative yield in three steps. We assumed that the product would be formed from intermediate **5** via pathway b. However, the product **6** might be also formed from intermediate **4** via pathway a through reduction of ketone to alcohol followed by elimination (Scheme 1).



In order to confirm the reaction route, we tried to synthesize a known azepine compound,<sup>5</sup> hexahydroapoerysopine **11** using enone-ester **9** which could induce a sequential cyclization. The compound **9** was synthesized from  $7^{6,8}$  by the Suzuki coupling reaction with vinyl iodide **8** in 78% yield. The iodide compound **8** was prepared from the corresponding enone by iodination





<sup>\*</sup> Corresponding author. Tel.: +82 42 821 5475; fax: +82 42 821 8896. *E-mail address:* guncheol@cnu.ac.kr (G. Kim).

<sup>0040-4039/\$ -</sup> see front matter @ 2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.tetlet.2013.01.093



followed by elimination.<sup>9</sup> Application of the same conditions to **9** provided **10** in 80% yield, which showed that the initial cyclization should be carried out by amine–carbonyl condensation. Hydrogenation followed by hydride reduction of **10** provided the known **11** in 97% yield (Scheme 2).<sup>10</sup>

Additionally we want to examine the amine cyclization with conjugate ester and imide moieties. First, we prepared a few substrates to figure out the addition reaction aspects on the  $\alpha$ , $\beta$ -unsaturated carbonyl compounds. The substrates **14** could be readily prepared through Suzuki coupling between **7** and vinyl bromide **13** in moderate yields. Although the yields were not satisfactory, we just wanted to find the results of the next reaction instead of optimizing the reaction with vinyl iodide derivatives of **13**. Upon treatment of **14a** or **14b** with CF<sub>3</sub>COOH in CH<sub>2</sub>Cl<sub>2</sub> at rt followed by concentration and basification with K<sub>2</sub>CO<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, Michael addition has been found

# Table 1

Study of cyclization 14<sup>11</sup>

to proceed at rt to afford seven-membered azepine ring products  $15a^{12}$  or 15b as a single isomer in 99% or 70% yield respectively (Table 1: entries 1 and 2). However, for imide derivatives, **14c** or **14d**, six-membered ring compounds **15c** or **15c**' containing a quaternary center were formed favorably via 6-*exo* addition mode over the seven-membered ring compound **15d** or **15d**' in 2:1 ratio (entries 3 and 4) in 98% combined yields.<sup>13</sup> As expected, ester or imide moieties allowed only Michael type addition reactions differently from  $\alpha$ , $\beta$ -unsaturated carbonyl compounds.

In summary, we could synthesize a tricyclic azepine compound, hexahydroapoerysopine **11** via an aza-cyclization reaction through free amine–carbonyl condensation of  $\alpha$ , $\beta$ -unsaturated ketone followed by sequential reduction. The cyclization of conjugate esters and imides has been investigated under the same condition. In the case of  $\alpha$ , $\beta$ -unsaturated esters, Michael type addition was exclusive to afford the seven-membered ring, however,  $\alpha$ , $\beta$ -unsaturated imides have afforded six-membered ring compounds dominantly via *exo*-type Michael addition. Further synthetic application is under study.

# Acknowledgment

This work was supported by the Korea Research Foundation Grant Funded by Korean Government (KRF-2011-0015865).

# **References and notes**

- (a) Cordell, G. A. In *The Alkaloids: Chemistry and Pharmacology*; Academic Press: San Diego, 1998; Vol. 50, (b) Weinstock, J.; Hieble, J. P.; Wilson, J. W. *Drugs Future* **1985**, *10*, 645–651; (c) Padwa, A.; Beall, L. S.; Eidell, C. K.; Worsencroft, K. J. J. Org. Chem. **2001**, 66, 2414–2421.
- (a) Fajardo, V.; Elango, V.; Cassels, B. K.; Shamma, M. *Tetrahedron Lett.* **1982**, *23*, 39–42; (b) Valencia, E.; Freyer, A. J.; Shamma, M.; Fajardo, V. *Tetrahedron Lett.* **1984**, *25*, 599–602.



- 3. (a) Couture, A.; Deniau, E.; Grandclaudon, P.; Hoarau, C. Tetrahedron 2000, 56, 1491-1499; (b) Padwa, A.; Beall, L. S.; Eidel; Worsencroft, K. J. J. Org. Chem. 2001, 66, 2414-2421; (c) Yoda, H.; Nakahama, A.; Koketsu, T.; Takabe, K. Tetrahedron Lett. 2002, 43, 4667-4669; (d) Kim, G.; Kim, J. H.; Kim, W.; Kim, Y. A. Tetrahedron Lett. 2003, 44, 8207-8209; (e) Yoda, H.; Inoue, K.; Ujihara, Y.; Mase, N.; Takebe, K. Tetrahedron Lett. 2003, 44, 9057-9060; (f) Koseki, Y.; Katsura, S.; Kusano, S.; Sakata, H.; Sato, H.; Monzene, Y.; Nagasaka, T. Heterocycles 2003, 59, 527–540; (g) Sahakitpichan, P.; Ruchirawat, S. Tetrahedron 2004, 60, 4169–4172; (h) Honda, T.; Sakamaki, Y. Tetrahedron Lett. 2005, 46, 6823–6825; (i) Tomasevich, L. L.; Kennedy, N. M.; Zitelli, S. M.; Hull, R. T., II.; Gillen, C. R.; Lam, S. K.; Baker, N. J.; Rohanna, J. C.; Conley, J. M.; Guerra, M. L.; Starr, M. L.; Sever, J. B.; Carroll, P. J.; Leonard, M. S. Tetrahedron Lett. 2007, 48, 599-602; (j) Fuwa, H.; Sasaki, M. Org. Biomol. Chem. 2007, 5, 1849-1853; (k) Kim, G.; Lee, K. Y.; Yoo, C.-H. Synth. Commun. 2008, 38, 3251-3259; (1) Fuwa, H.; Sasaki, M. Heterocycles 2008, 76, 521-539; (m) Onozaki, Y.; Kurono, N.; Senboku, H.; Tokuda, M.; Orito, K. J. Org. Chem. 2009, 74, 5486-5495; (n) Piko, B. E.; Keegan, A. L.; Leonard, M. S. Tetrahedron Lett. 2011, 52, 1981-1982
- (a) Kim, G.; Jung, P.; Tuan, L. A. *Tetrahedron Lett.* 2008, 49, 2391–2392; (b) Oh, K. R.; Kim, G. Bull. Korean Chem. Soc. 2012, 33, 3933–3934.
- (a) lida, H. I.; Takarai, T.; Kibayashi, C. J. Org. Chem. **1978**, 43, 975–979; (b) lida, H. I.; Takarai, T.; Kibayashi, C. J. Chem. Soc., Chem. Commun. **1977**, 644–645.
  Pandey, G.; Balakrishnan, M. J. Org. Chem. **2008**, 73, 8128–8131.
- Appukkuttan, P.; Dehaen, W.; Van der Eycken, E. Comb. Chem. High Throughput Screening 2007, 10, 790–801.

- Johnson, C. R.; Adams, J. P.; Braun, M. P.; Senanayake, B. W.; Wovkulich, P. M.; Uskokovic, M. R. *Tetrahedron Lett.* **1992**, 33, 917–918.
- 9. Dubé, D.; Scholte, A. A. Tetrahedron Lett. 1999, 40, 2295-2298.
- 10. Spectral data of **11** were identical to those of the known.<sup>5</sup>
- 11. Reaction conditions for 14: A mixture of 7 and 4 in dioxane:H<sub>2</sub>O (3:1) containing Pd(PPh<sub>3</sub>)<sub>4</sub> (4%) and Na<sub>2</sub>CO<sub>3</sub> (2 equiv.) was heated at 150 °C in a sealed tube for 7 min. 15: a solution of 14 in TFA: CH<sub>2</sub>Cl<sub>2</sub> (1:1) was stirred at rt for 30 min. Concentration and treatment with excess K<sub>2</sub>CO<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> at rt were followed by routine work-up and purification.
- Compound **15a** has been characterized more cleanly after acylation of amine, Ac- **15a**: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 1.95 (s, 3H), 2.80–3.08 (m, 4H), 3.59 (m, 2H), 3.86 (s, 3H), 3.87 (s, 3H), 4.46 (dd, 1H, *J* = 10.9, 2.1 Hz), 4.67 (dd, 1H, *J* = 10.9, 7.6 Hz), 5.95 (dd, 1H, *J* = 9.2, 7.6 Hz), 6.66 (s, 1H), 6.73 (s, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) 21.94, 31.62, 41.25, 48.79, 50.29, 55.92, 56.07, 69.95, 113.54, 115.42, 123.86, 127.75, 148.05, 149.03, 171.12, 176.36, EIMS 306.34 (M\*).
- The ratio has been detected by <sup>1</sup>H NMR, because pure separation of the two isomers was hard. Compound **15d** has also been characterized more cleanly after acylation of amine, Ac-**15d**. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 2.28 (s, 3H), 2.83 (ddd, 1H, *J* = 12.0, 4.0, 4.0 Hz), 3.15 (ddd, 1H, *J* = 12.0, 8.0, 4.0 Hz), 3.18 (d, 1H, *J* = 17.9 Hz), 3.40 (d, 1H, *J* = 17.9 Hz), 3.52 (ddd, 1H, *J* = 12.0, 8.0, 4.0 Hz), 3.18 (d, 1H, *J* = 17.9 Hz), 3.89 (s, 3H), 4.03 (ddd, 1H, *J* = 12.0, 4.0, 4.0 Hz), 6.62 (s, 1H), 6.71 (s, 1H); 7.34–7.50 (m, 5H) <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) 23.02, 30.10, 44.26, 45.25, 56.33, 56.47, 63.57, 107.10, 112.03, 126.53, 126.99, 128.37, 129.06, 129.62, 132.80, 149.21, 149.43, 170.94, 174.54, 176.03.